A total of 45,048 patents were granted across pharma industry between July 2021 and September 2021, marking a 5.71% drop over the previous quarter (April 2021-June 2021), according to GlobalData Patents Database.
Patenting activity by top assignee
Go deeper with GlobalData
Out of 9,152 active assignees during the review quarter, Bayer registered a growth change of -2% with 205 patent grants, followed by Bristol-Myers Squibb with -4% (200), F. Hoffmann-La Roche with -10% (342), Johnson & Johnson with -19% (340) and LG with -24% (235).
| Filings | Grants |
Oncology was the most active therapy area/indication with 252 patent grants, followed by Solid Tumor with 62 and Viral Infections with 50.
See Also:
The least active IP protected therapy area/indications include Alzheimer’s Disease and Crohn’s Disease (Regional Enteritis) with 24 and 22 patent grants, respectively.
Assignee highest and lowest growth rate
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOvid Therapeutics; POET Research; and Denali Therapeutics saw the leading growth rates of 900%; 600%; and 500%, respectively in patent grants during Jul-Sep 2021 compared with the previous three-month period, while PAI Partners saw the lowest growth rate of -93.8%.
Patenting activity: Leading themes in the Jul-Sep 2021 quarter
Rare Diseases led the pharma sector with 7,446 patents during the review quarter, followed by Regenerative Medicine and Nanomedicine with 1,964 and 1,707 patents, respectively.
Patenting activity: Therapy area/Indication composition
In terms of therapy area/indication, Oncology led IP protection with 4,488 patent grants during the review quarter, followed by Solid Tumor with 1,908, Ocular Inflammation with 708, Inflammation with 705, and Diabetes with 661.
IP protection activity by region
China led IP protection activity with 18,062 grants and 26,777 new filings during the Jul-Sep 2021 quarter, followed by the US with 5,481 grants and 9,657 new filings.
Japan came in next with 3,805 grants and 6,664 new filings. European Patent Office (EP) and WIPO (WO) stood next with 3,044 grants and 5,707 new filings; grants and 8,133 new filings, respectively.
New entrants in Jul-Sep 2021
AIST, Bahcesehir University, Aelin Therapeutics, Bit Bio and PearlRiver Bio are the five new entrants in the Pharma industry with 18, three, three, two and one patent filings, respectively during the Jul-Sep 2021 quarter.
Methodology:
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus. Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
For generation of above insights, we have considered the 120,293 documents published during the period of July 2021 to September 2021. This data was tagged to 21 themes, 1,997 sectors, 9,084 assignees, 255,309 inventors and 56 countries.
Additional details on above insights are available on GlobalData’s suite of platforms or contact us directly for further engagement.
Disclaimer: All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, GlobalData can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.
